Abstract:Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly produce acute self-limited episodes in poor income regions and in non-vaccinated travelers. In high-income countries, outbreaks of hepatitis A occur in men having sex with men (MSM) and chronic hepatitis E is occasionally reported among PLWH with severe immunodeficiency. Chronic hepatitis B, C, and D are frequent in PLWH in highly endemic regions and globally in persons who inject drugs (PWID) and MSM. Progression to liver cirrhosis and development of hepatocellular carcinoma (HCC) is major clinical complications in coinfected patients. Current estimates for PLWH are of 38 million worldwide. Roughly 12% have chronic viral hepatitis (5 million). Coinfection figures are of 5-10% for HBV (2-4 million), 4% for HCV (1.5 million), and 15% of HBsAg+ for HDV (0.5 million). Oral direct-acting antivirals (DAA) cure almost all treated patients with hepatitis C. However, given that there is no protective HCV immunity, PLWH with high-risk behaviors may experience HCV reinfection episodes. Tenofovir is the drug of choice in PLWH with chronic hepatitis B, given its dual effect on HIV and HBV. Lifelong oral tenofovir suppresses HBV replication and ameliorate liver damage. However, the risk of HCC persists even in the absence of cirrhosis. Finally, HDV causes the worst of viral hepatitis with faster progression to cirrhosis and HCC. An entry inhibitor, bulevirtide, has recently been approved and another drug, lonafarnib, is completing Phase 3 trials. Combination antiviral therapy for hepatitis D could improve dramatically the poor prognosis of HIV-HDV coinfected patients. The resumption of good medical practices in PLWH after the big disruption caused by COVID-19 will reduce the burden of viral hepatitis coinfections. Renewed efforts on HAV and HBV vaccination of susceptible individuals and earlier and wider prescription of antiviral therapy for HBV, HCV, and/or HDV coinfection should be prioritized in PLWH. The benefits of innovative strategies for viral hepatitis, including pre-exposure prophylaxis or use of long-acting antivirals, warrant further consideration in PLWH.

Acute Hepatitis Due to Primary Human Immunodeficiency Virus Infection

Acute human immunodeficiency virus infection associated hemophagocytic lymphohistiocytosis

Autoimmune hepatitis in human immunodeficiency virus-infected patients: A case series and review of the literature

Clinical and Epidemiologic Features of Primary HIV Infection

Hemophagocytic Lymphohistiocytosis Secondary to Acute Human Immunodeficiency Virus and COVID-19

Acute HIV infection presenting as hemophagocytic syndrome with an unusual serological and virological response to ART

Hepatitis B and human immunodeficiency virus coinfection

Human Cytomegalovirus and Epstein-Barr Virus Infections, Risk Factors, and Their Influence on the Liver Function of Patients with Acute-on-chronic Liver Failure

[Diagnostics of the HIV infection]

[Acute primary stage of HIV infection with documented seroconversion]

Acute liver failure caused by lymphocyte-depleted Hodgkin lymphoma in tuberculosis and HIV-infected patient

Hepatitis B–Related Hepatic Flare During Immune Reconstitution Syndrome After Antiretroviral Treatment Initiation in an HBV Surface Antigen–Positive Patient With HIV: Viroimmunological and Histological Characterization

Hemophagocytic Lymphohistiocytosis Associated With Parvovirus B19 in a Patient With Acquired Immunodeficiency Syndrome

S4589 Rare Case of Acute Liver Failure Secondary to a Disseminated VZV Infection

Cytokine network and acute primary HIV-1 infection

S2376 A Curious Case of AIDS Cholangiopathy

A case of successful treatment with antiretroviral therapy for HIV in a patient with marked liver dysfunction

Viral hepatitis in persons living with HIV in the post-COVID era

A special case of acute portal vein thrombosis

S5087 Chicken Pox of the Gut in a Patient With Advanced HIV

S4659 Navigating Diagnostic Challenges: Herpes Simplex Virus as an Uncommon Cause of Acute Liver Failure in a Low-Risk Patient